Adaptive Biotechnologies Corp Stock Today
| ADPT Stock | USD 5.73 0.05 0.88% |
Performance6 of 100
| Odds Of DistressOver 51
|
Adaptive Biotechnologies is selling for under 5.73 as of the 28th of November 2024; that is 0.88% increase since the beginning of the trading day. The stock's last reported lowest price was 5.52. Adaptive Biotechnologies has 51 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Adaptive Biotechnologies Corp are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of August 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of June 2019 | Category Healthcare | Classification Health Care |
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington. The company has 147.58 M outstanding shares of which 8.2 M shares are presently shorted by private and institutional investors with about 7.86 trading days to cover. More on Adaptive Biotechnologies Corp
Moving against Adaptive Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Adaptive Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO CoFounder | Chad MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Health Care, Life Sciences Tools & Services, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAdaptive Biotechnologies can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Adaptive Biotechnologies' financial leverage. It provides some insight into what part of Adaptive Biotechnologies' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adaptive Biotechnologies Corp (ADPT) is traded on NASDAQ Exchange in USA. It is located in 1165 Eastlake Avenue East, Seattle, WA, United States, 98109 and employs 709 people. Adaptive Biotechnologies is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 838.25 M. Adaptive Biotechnologies conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 147.58 M outstanding shares of which 8.2 M shares are presently shorted by private and institutional investors with about 7.86 trading days to cover.
Adaptive Biotechnologies Corp currently holds about 383.74 M in cash with (156.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69.
Check Adaptive Biotechnologies Probability Of Bankruptcy
Ownership AllocationAdaptive Biotechnologies holds a total of 147.58 Million outstanding shares. The majority of Adaptive Biotechnologies Corp outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Adaptive Biotechnologies to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Adaptive Biotechnologies. Please pay attention to any change in the institutional holdings of Adaptive Biotechnologies Corp as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Adaptive Ownership Details
Adaptive Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-09-30 | 2.7 M | |
| State Street Corp | 2024-06-30 | 2.5 M | |
| Blue Water Life Science Advisors, Llc | 2024-09-30 | 2.1 M | |
| Soleus Capital Management, L.p. | 2024-06-30 | 1.7 M | |
| Pictet Asset Manangement Sa | 2024-06-30 | 1.7 M | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.4 M | |
| Pier Capital, Llc | 2024-09-30 | 1.3 M | |
| Bank Of America Corp | 2024-06-30 | 1.1 M | |
| Goldman Sachs Group Inc | 2024-06-30 | 1 M | |
| Viking Global Investors Lp | 2024-09-30 | 30 M | |
| Rubric Capital Management Lp | 2024-06-30 | 14 M |
Adaptive Biotechnologies Historical Income Statement
Adaptive Stock Against Markets
Adaptive Biotechnologies Corporate Management
| Stacy JD | General VP | Profile | |
| Stacy Taylor | General VP | Profile | |
| Yi Zhou | Chief Officer | Profile | |
| Tycho Peterson | Chief Officer | Profile | |
| Kyle Piskel | Principal Officer | Profile | |
| Susan Bobulsky | Chief MRD | Profile |
Already Invested in Adaptive Biotechnologies Corp?
The danger of trading Adaptive Biotechnologies Corp is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Adaptive Biotechnologies is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Adaptive Biotechnologies. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Adaptive Biotechnologies is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.